OS Therapies Inc OSTX
("OS Therapies," the "Company," "we," "our" or "us") is a clinical stage biopharmaceutical
company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. Our
mission is to address the significant need for new treatments in cancers of the bone in children and young adults. Osteosarcoma is an
extremely challenging and often aggressive cancer that has particular treatment challenges due to its location, changing genotypes and
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| R&D | $16.4M | $2.8M | $3.2M | — |
| SG&A | $12.3M | $4.0M | $1.1M | — |
| Operating income | -$28.7M | -$6.8M | -$4.3M | — |
| Interest expense | — | $2.1M | $3.4M | — |
| Net income | -$28.8M | -$8.9M | -$7.8M | — |
| EPS, basic | -0.98 | -1.28 | -1.46 | — |
| EPS, diluted | -0.98 | -1.28 | -1.46 | — |
| Shares, diluted (wtd. avg.) | $29.3M | $7.0M | $5.4M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $269.8K | $5.5M | $39.0K | $171.5K |
| Total current assets | $332.9K | $5.5M | $790.0K | — |
| Property, plant and equipment | $2.5K | $5.3K | $8.1K | — |
| Other intangibles | $6.5M | — | — | — |
| Total assets | $6.8M | $5.5M | $798.1K | — |
| Accounts payable | $9.9M | $1.7M | $2.7M | — |
| Short-term debt | — | — | $100.0K | — |
| Total current liabilities | $11.8M | $4.6M | $24.7M | — |
| Total liabilities | $11.9M | $4.7M | $24.8M | — |
| Retained earnings | -$67.2M | -$38.4M | -$29.5M | — |
| Total equity | -$6.1M | -$3.3M | -$24.0M | -$17.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | -$14.2M | -$7.3M | -$3.0M | — |
| Depreciation and amortisation | — | $2.8K | $4.2K | — |
| Stock-based compensation | $4.3M | $268.3K | — | — |
| Capital expenditure | $466.4K | — | — | — |
| Investing cash flow | -$466.4K | — | $1.1K | — |
| Financing cash flow | $9.4M | $12.8M | $2.9M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-036629.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |